Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2007

View Archived Issues

Neogenix selects GBI to manufacture its monoclonal antibody, NPC-1C

HemispheRx initiates Ampligen phase IIb trial for seasonal flu in Australia

Promising antitumor activity of thorium-labeled rituximab

Lupulone shows antiangiogenic activity in vitro and in vivo

Preliminary phase III results for CellCept in lupus nephritis

Alnylam advances RNAi therapeutic program into IND-enabling studies

Positive phase IIa results for Speedel's renin inhibitor for hypertension

Kythera completes enrollment for phase II trial of ATX-201

Roche and Merck & Co. patents report new agents for depression, psychosis and sleep disorders

Delcath includes fourth arm to phase II study of metastatic melanoma

New diagnostic agents reported by the Universities of Pittsburgh and Hong Kong

Acadia initiates phase IIb trial of ACP-104 for schizophrenia

Wilex begins enrollment for phase II trial for pancreatic cancer

New agents for endocrine-related disorders imparted in recent patent literature

FDA grants fast track designation for HCV-796

Alnylam initiates phase II trial of ALN-RSV01 for RSV

Organon signs asset purchase agreement for Kadmus' FAAH technology

New phase III trial studies sunitinib malate in metastatic colorectal cancer

Wyeth licenses osteoporosis drug targets from Galapagos collaboration

Largest international study of patients on dialysis begins in Europe

NanoEmulsion diclofenac cream begins phase IIa study

Amendment to Lialda agreement

Schering-Plough will not enter new exclusivity period to negotiate celgosivir license

Highly immunogenic ribosomal-based vaccine protects against Shigella infection

CH-1504 begins bioequivalence study

Priority review for Taxotere sNDA in head and neck cancer

ALT-2074 begins phase II study in patients with diabetes and Hp2-2

Vyvanse filed for ADHD in adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...